Medical/Pharmaceuticals

Brii Bio Presents Positive Phase 3 Data on BRII-196/BRII-198, the Company's SARS-CoV-2 Monoclonal Neutralizing Antibody Combination Therapy, in an Oral Late-Breaker Presentation at IDWeek 2021

DURHAM, N.C.and BEIJING, Oct. 4, 2021 /PRNewswire/ -- Brii Biosciences  Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health ...

2021-10-04 08:00 4794

Colorectal cancer diagnoses dropped over 40% during COVID-19 pandemic, new study shows

VIENNA, Oct. 4, 2021 /PRNewswire/ -- The number of colorectal cancer (CRC) cases diagnosed fell dramatically by 40% in a year during the COVID-19 pandemic, new research presented today at UEG Week Virtual 2021 has shown. The research, which was conducted across multiple hospitals in Spain, compa...

2021-10-04 06:00 2835

In Lead-up to Breast Cancer Awareness Month, New Hologic Global Women's Health Index Finds Globally Most Women Were Not Checked for Any Cancer in Past Year

Worldwide, 88% of women said in 2020 that they had not been tested for any type of cancer in the past 12 months. Most women believe checkups help improve health, but 40% haven't talked to a healthcare professional in the past 12 months. WASHINGTON, Oct. 2, 2021 /PRNewswire/ -- In the lead-up to ...

2021-10-02 12:18 3931

World's Leading Neuroscientists Unveil Research on COVID-19's Impact on the Brain, Understanding Migraine Pathophysiology, Solving the Mystery of Sleep, Biomarkers in Traumatic Brain Injury and More at 25th Biennial World Congress of Neurology from October 3-7

LONDON, Oct. 2, 2021 /PRNewswire/ -- The impact COVID-19 has on the brain, understanding migraine pathophysiology, solving the mystery of sleep by "Lighting Up the Brain," blood biomarkers for traumatic brain injury and more groundbreaking research will be unveiled by the world's leading neurosci...

2021-10-02 12:10 4934

CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th Annual Meeting of the American Thyroid Association 2021

* Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And the 9-month duration of response (DOR) rate was 100% ...

2021-10-02 08:30 10482
1 ... 639640641642643

Week's Top Stories